Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -60.19% is 20% below its 5-year average of -50.07%, around the middle of its 5-year range (-136.20%–-15.00%).
As of the fiscal period ended Tuesday, June 30, 2026. 19.14% above its 12-month average of -74.43%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -60.19%.
RETURN ON EQUITY (ROE)
-60.19%
RETURN ON EQUITY (ROE) AVG TTM
-74.43%
RETURN ON EQUITY (ROE) AVG 3Y
-59.65%
RETURN ON EQUITY (ROE) AVG 5Y
-50.07%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+19.14%
CURRENT VS 3Y AVG
-0.90%
CURRENT VS 5Y AVG
-20.21%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-40.09%
median of 643 covered companies
CURRENT VS SECTOR MEDIAN
-50.12%
vs the sector median at left
PepGen Inc.
Market Cap
$162.89M
Return on Equity (ROE)
-60.19%
TTM Avg
-74.43%
3Y Avg
-59.65%
5Y Avg
-50.07%
Market Cap
$163.00M
Return on Equity (ROE)
-215.26%
TTM Avg
-150.35%
3Y Avg
8.65%
5Y Avg
-35.35%
Market Cap
$164.16M
Return on Equity (ROE)
-51.90%
TTM Avg
-23.95%
3Y Avg
-20.95%
5Y Avg
-18.62%
Market Cap
$165.58M
Return on Equity (ROE)
3.51%
TTM Avg
-6.60%
3Y Avg
-9.04%
5Y Avg
-6.71%
Market Cap
$159.33M
Return on Equity (ROE)
N/A
TTM Avg
101.44%
3Y Avg
117.16%
5Y Avg
-25.56%
Market Cap
$157.57M
Return on Equity (ROE)
-14.07%
TTM Avg
-16.23%
3Y Avg
-27.66%
5Y Avg
-19.01%
Market Cap
$169.85M
Return on Equity (ROE)
-31.32%
TTM Avg
4.38%
3Y Avg
4.09%
5Y Avg
11.26%
Market Cap
$162.60M
Return on Equity (ROE)
N/A
TTM Avg
13.51%
3Y Avg
15.58%
5Y Avg
15.05%
Market Cap
$170.85M
Return on Equity (ROE)
-56.61%
TTM Avg
-75.88%
3Y Avg
-88.15%
5Y Avg
-30.55%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| PepGen Inc. (PEPG) | $162.89M | -60.19% | -74.43% | -59.65% | -50.07% |
| Coherus Oncology, Inc. (CHRS)vs › | $163.00M | -215.26% | -150.35% | 8.65% | -35.35% |
| Quanterix Corporation (QTRX)vs › | $164.16M | -51.90% | -23.95% | -20.95% | -18.62% |
| OptimizeRx Corp. (OPRX)vs › | $165.58M | 3.51% | -6.60% | -9.04% | -6.71% |
| Minerva Neurosciences, Inc. (NERV)vs › | $159.33M | N/A | 101.44% | 117.16% | -25.56% |
| Inogen, Inc. (INGN)vs › | $157.57M | -14.07% | -16.23% | -27.66% | -19.01% |
| Organogenesis Holdings Inc. (ORGO)vs › | $169.85M | -31.32% | 4.38% | 4.09% | 11.26% |
| Jyong Biotech Ltd. Ordinary Shares (MENS)vs › | $162.60M | N/A | 13.51% | 15.58% | 15.05% |
| MediWound Ltd. (MDWD)vs › | $170.85M | -56.61% | -75.88% | -88.15% | -30.55% |
| ALX Oncology Holdings Inc. (ALXO)vs › | $153.40M | -59.40% | -255.06% | -160.44% | -112.56% |
ROE
-60.2%
ROA
-50.9%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -60.19% |
| 2026-03-31 | -57.63% |
| 2025-12-31 | -60.81% |
| 2025-09-30 | -57.35% |
| 2025-06-30 | -136.20% |
| 2025-03-31 | -111.28% |
| 2024-12-31 | -75.86% |
| 2024-09-30 | -63.46% |
| 2024-06-30 | -57.49% |
| 2024-03-31 | -44.88% |
| 2023-12-31 | -72.52% |
| 2023-09-30 | -58.85% |
| 2023-06-30 | -47.11% |
| 2023-03-31 | -40.75% |
| 2022-12-31 | -38.47% |
| 2022-09-30 | -31.78% |
| 2022-06-30 | -24.17% |
| 2022-03-31 | -33.65% |
| 2021-12-31 | -20.50% |
| 2021-09-30 | -15.00% |
| 2021-06-30 | -90.81% |
